Biofabrication Market

Biofabrication Market Analysis

The Biofabrication Market size is estimated at USD 2.79 billion in 2025, and is expected to reach USD 5.27 billion by 2030, at a CAGR of 13.60% during the forecast period (2025-2030).

The major factors driving the studied market are the increasing demand for regenerative medicine, growing technological advancements in 3D bioprinting technology, rising clinical advantages of bio-fabrication 3D printing in healthcare, and rising demand for organ transplants and tissue engineering.

Organ transplantation is a medical procedure that involves replacing a diseased or failing organ with a healthy one from a donor. The unavailability of adequate organs for transplantation to meet the existing demand is a major challenge in the medical field. Biofabricated organs can provide patients with safer and more effective transplants. Hence, the increasing demand for organ transplantation is expected to drive the demand for biofabrication, thereby driving the studied market over the forecast period.

For instance, as per the data published by the Human Resources and Services Administration (HRSA) organdonor.gov, around 103,223 individuals are on the national transplant waiting list in the United States in 2024. Additionally, as per the same source, another individual is added to the transplant waiting list every eight minutes. Hence, the increasing demand for organ transplantation is expected to increase the demand for biofabrication technologies, which will ultimately drive the studied market over the forecast period.

Further, the increasing technological advancements in the fabrication field are also expected to increase the accessibility of these technologies across the globe, which will further drive the studied market over the forecast period. For instance, in October 2023, Cellink, a bioprinting technologies provider, reported the launch of Cellink Vivoink, a medical-grade bio-ink bioprinter used in regenerative medicine and tissue engineering fields. This device is optimized for superior printability, mechanical stability, and cell viability for fabrication. Hence, such technological advancements are expected to increase the accessibility of biofabrication devices, which will ultimately drive the studied market over the forecast period.

Furthermore, the increasing investments by the government are also expected to accelerate the development of fabrication 3D printing technologies, which will ultimately drive the studied market over the forecast period. For instance, in July 2023, Aspect Biosystems Ltd. received USD 72.7 million in investment from the Governments of Canada and British Columbia. This investment is expected to be utilized for the multi-year project to advance the company's unique clinical biomanufacturing capabilities, full-stack tissue therapeutic platform, and pipeline of bioprinted tissue therapeutics. Hence, such investments by the government are expected to increase the utilization of biofabrication technologies, which further drive the studied market over the forecast period.

Thus, the increasing demand for organ transplantation, rising technological advancements in the biofabrication field, and growing government initiatives are expected to drive the studied market over the forecast period. However, the high cost of technology and materials is expected to restrain the studied market over the forecast period.

Biofabrication Market Trends

Tissue Engineering Segment is Expected to Hold Significant Market Share Over the Forecast Period

Tissue engineering uses a combination of cells, engineering, materials methods, and suitable biochemical and physicochemical factors to restore, maintain, improve, or replace different types of biological tissues. The goal of tissue engineering is to assemble functional constructs that restore, maintain, or improve damaged tissues or whole organs. The increasing investment in tissue engineering and rising strategic activities, such as the launch of new tissue-engineered products by key players, are expected to drive the segment revenue over the forecast period.

The increasing investments in tissue engineering drive the research activities for the development of biofabrication printing technologies and increase the affordability of biofabrication products, thereby propelling the studied market growth over the forecast period. For instance, in December 2024, the United States National Science Foundation (NSF) offered funding for up to USD 1.6 million for proposals to leverage the biofabrication facility in the International Space Station (ISS) National Laboratory to enhance tissue engineering.

Additionally, in March 2024, TissueLabs received USD 800 thousand in a pre-seed round from Mergus Ventures. TissueLab’s mission was to produce synthetic tissues and organs for therapeutic applications. The company's product portfolio includes advanced 3D bioprinters, tissue-specific biomaterials, and specialized software. Hence, such investments in startup companies are expected to drive the launch of novel biofabrication technologies, which ultimately drive the studied market over the forecast period.

Furthermore, the increasing strategic activities, such as the collaborations by key market players are also expected to increase the accessibility of the biofabircation technologies, which ultimately drive the studied market over the forecast period. For instance, in March 2024, BIO INX revealed its strategic partnership with Rousselot. Through this collaboration, BIO INX distributed Rousselot's research and technical grade X-Pure gelatin biomaterials. The online purchasing system simplifies the ordering process and ensures prompt delivery of high-quality gelatins essential for tissue engineering and biofabrication projects. Hence, such strategic activities by the key players in the market are expected to drive the studied segment revenue over the forecast period.

Thus, the increasing investments in tissue engineering and growing strategic activities by key players in the market are expected to increase the accessibility and affordability of biofabrication technologies, which will ultimately drive the studied market over the forecast period.

North America is Expected to Hold the Significant Market Share Over the Forecast Period

The biofabrication market in North America is driven by factors such as the growing research and development activities in the biofabrication field, advanced healthcare systems, and increasing strategic activities by key players in the market.

The increasing demand for organ transplantation in North America is expected to fuel the utilization of biofabrication technologies to produce tissue that can transform its properties based on internal or external stimuli over time, similar to natural tissue. For instance, according to the Canadian Institute of Health Information from the January 2024 update, a total of 3,427 Canadians were on wait lists to receive a transplant as of December 2023, 60% were active on wait lists, and 40% were on hold for a short period of time. Hence, the rising demand for organ transplantation accelerates the research activities in 3D bioprinting, thereby boosting the studied market over the forecast period.

Furthermore, the increasing investments in bioprinting increase the accessibility of biofabrication technologies in healthcare and drive the studied market over the forecast period. For instance, in October 2024, Biological Lattice Industries Corp. revealed the successful completion of a USD 1.8 million pre-seed investment round, which was spearheaded by the Greek venture capital company Uni.Fund. Alongside this funding, BLI launched its all-in-one biofabrication solution in the United States, BioLoom, an advanced multi-tool 3D bioprinter, paired with Loominus Studio, a unified software platform aimed at transforming biofabrication workflows with enhanced precision, reproducibility, and efficiency.

Additionally, in July 2023, 3D BioFibR, a Canadian company, raised over USD 3.52 million to bring its bio-printed collagen fiber products to market. The funding will advance the company’s capabilities in manufacturing high-quality collagen fibers, highlighting the evolving landscape of biofabrication as it progresses from research to market-ready solutions. Hence, such investments are expected to increase the accessibility to biofabrication technologies products in the market, which ultimately drive the studied market over the forecast period.

Hence, the increasing organ transplantation across the region and growing investment in bioprinting technologies is expected to increase the accessibility of the biofabrication technologies across the North America, which ultimately drive the studied market over the forecast period.

Biofabrication Industry Overview

The biofabriaction market is fragmented due to the presence of many global and regional players in the field. The major players in the market are adopting various strategic activities such as mergers, collaborations, and raising funds for new solutions development. Some of the key players in the market are Organovo Holdings Inc., EnvisionTEC, Aspect Biosystems Ltd., Allevi Inc., and Stratasys Ltd., and among other players.

Biofabrication Market Leaders

Biofabrication Market News

• November 2024: The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) created the India's first homegrown patented bioink formulation that can be utilized for the biofabrication of tissues such as the liver, kidney, pancreas, skin, brain, and heart through cutting-edge three-dimensional (3D) bioprinting technology. The component of this bioink is a chemically altered gelatin known as gelatin methacrylamide (GelMA).
• June 2024: CTIBIOTECH unveiled its latest project, SAFESKIN3D, in collaboration with SANOFI. This innovative initiative seeks to develop flexible 3D bioprinted human skin models to forecast the reactogenicity of vaccines, especially the next generation of messenger RNA (mRNA) vaccines.